May 20, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Advances in Psoriasis and Inflammatory Skin Diseases

» Advanced search

Latest Issue

Volume 1 Issue 1

Leading ArticlesClick to expand
- The Role of Host Defense Peptides in the Development and Pathogenesis of Psoriasis
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)
  
  Jürgen Schauber, MD
  
  Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians University, Munich, Germany 
  
  The production of antimicrobial peptides (AMPs) by resident and infiltrating cells is a primary defense system in cutaneous innate immunity. The β-defensins and the cathelicidins are two families of AMPs that protect the skin through distinct pathways: direct antimicrobial activity against an array of pathogens, and initiation of a host response that results in cytokine release and inflammation. The multiple roles of AMPs prompted their alternative designation as “alarmins”, and AMP dysregulation or dysfunction emerges as a central factor in the pathogenesis of several cutaneous diseases, including psoriasis.
  
  » Read more
- HRQL Outcomes for Assessing Effectiveness in Clinical Trials of Biological Agents for Psoriasis: A Systematic Review
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)
  
  Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, and Dennis A Revicki, PhD
  
  Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA 
  
  Increasing evidence has shown that treatment with biological therapies reduces the symptoms of plaque psoriasis, with concomitant improvements in health-related quality of life (HRQL). However, these HRQL instruments require evidence supporting their systematic development and psychometric properties to best provide meaningful outcome information. The objectives of this review were to identify and critically appraise patient-reported outcome instruments used in clinical trials of biological agents in patients with psoriasis in the past 10 years, and to evaluate the impact of treatment with biological agents in clinical trials with patients who have moderate-to-severe plaque psoriasis.
  
  » Read more
- Advances in Biological Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Adalimumab, Efalizumab, Alefacept, and Ustekinumab
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)
  
  Jeffrey M. Weinberg, MD.
  
  Department of Dermatology, St Luke’s–Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
  
  Psoriasis is a chronic skin disorder that affects approximately 2% of the population of the US and Europe. Over the past several years, one of the major focuses of psoriasis research has been developing biological therapies that can be used to treat this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side-effects than traditional therapies.
  
  » Read more
Case StudyClick to expand
- Neutrophilic Dermatoses in Association with Portal Vein Thrombosis: A Case Report
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Case Study)
  
  Helen MacIver, MD.
  
  A 36-year-old female was initially referred to rheumatology outpatients at a district general hospital in Yorkshire, UK, with a 6-month history of rash, with red lumps around both knees that faded quickly without scarring.
  » Read more
Clinical ReviewsClick to expand
- Biological Therapies
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)
  
  » Read more
- Psoriatic Arthritis
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)
  
  » Read more
- Dermatoses in Children and Neonates
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)
  
  » Read more
- Epidemiology
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)
  
  » Read more
- Miscellaneous
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)
  
  » Read more
AppendixClick to expand
- Health-Related Quality-of-Life Outcomes for Assessing Effectiveness in Clinical Trials of Biological Treatments for Moderate-to-Severe Psoriasis: A Systematic Review: Appendix 1
  
  in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Appendix)
  
  Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, Dennis A Revicki, PhD
  
  Summary of psoriasis trials: population, design, and methods.
  
  » Read more

« Back

READER POLL

Which therapy would you first use to treat a patient with newly diagnosed, severe plaque psoriasis?

Topical agents
Methotrexate
Anti-TNF agents
Cyclosporine
Phototherapy
Other

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 20, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

Latest Issue

Volume 1 Issue 1

Leading Articles

Jürgen Schauber, MD

Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, and Dennis A Revicki, PhD

Jeffrey M. Weinberg, MD.

Case Study

Helen MacIver, MD.

Clinical Reviews

Appendix

Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, Dennis A Revicki, PhD

Volume 1 Issue 1

Leading ArticlesClick to expand

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)

Jürgen Schauber, MD

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)

Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, and Dennis A Revicki, PhD

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Leading Articles)

Jeffrey M. Weinberg, MD.

Case StudyClick to expand

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Case Study)

Helen MacIver, MD.

Clinical ReviewsClick to expand

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Clinical Reviews)

AppendixClick to expand

in Advances in Psoriasis and Inflammatory Skin Diseases (Volume 1 Issue 1 / Appendix)

Miriam Kimel, PhD, Jill A Bell, PhD, Chris Sexton, PhD, Dennis A Revicki, PhD

READER POLL

Post Page On

SUBMIT AN ARTICLE

May 20, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us